CytomX Therapeutics CTMX Varseta-M Ep CAM — Total External Costs

Similar metrics at other companies

ARVNVepdegestrant ARV-471 — Program-specific external expense

$8.9M-63.1%

ARVNARV-102 — Program-specific external expense

$5.5M-15.4%

ARVNOther programs — Program-specific external expense

$2.6M+52.9%

ARVNARV-393 — Program-specific external expense

$3.7M+42.3%

SLSTotal costs & expenses

$9.25M+52.6%

ARVNBavdegalutamide (ARV-110) — Program-specific external expense

$200K-81.8%

Questions, answered.

What is CytomX Therapeutics's varseta-m ep CAM — total external costs?

CytomX Therapeutics (CTMX) reported varseta-m ep CAM — total external costs of $7.81M in Q1 2026.

What does varseta-m ep CAM — total external costs mean?

This metric represents the aggregate third-party expenditures directly attributable to the research, development, and clinical advancement of the Varseta-M Ep CAM therapeutic program. It encompasses costs such as contract research organization fees, manufacturing outsourcing, and external clinical trial site expenses. Monitoring these costs provides insight into the capital intensity and operational efficiency of specific pipeline assets.